reports
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzo...
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S. Food and Dr...
aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Confere...
aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Piper Sandler 37th Annual Healthcare Conference, which is scheduled to take place December 2 – 4, 2025, in New York, NY. Details of the presentation appears below: Conference:...
aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporat...
aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026. Company expects to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) in the first half of 2026. Ended the third quarter 2025 with $92.9 million in cash, cash equivalents, restricted cash and investments. SAN DIEG...
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study ...
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025 Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0226). Improvement in King’s Sarcoidosis Questionnaire-General Health score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0197). SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- ...
aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of ...
aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid withdrawal at week 48 vs 40.2% on placebo (p=0.0919). Clinical improvement in King’s Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo...
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635...
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted three employees nonstatutory stock options to purchase an aggregate of 62,400 shares of aTyr’s common stock, each with an exercise price of $5.71 per share, which is eq...
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corpora...
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline results expected in mid-September 2025. SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2025 results and provided a corporate update. “With the recent complet...
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of...
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis Topline results expected in the third quarter of 2025. SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the last patient has completed their last visit in the Company’s Phase 3 EFZO-FIT™ study of its lead therapeutic candidate, efzofitimod...
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company is expected to be added to the Russell 2000® Index and broad market Russell 3000® Index, effective after the U.S. market close on June 27, 2025, as part of the 2025 Russell U.S. Indexes annual reconstitution. The Russell 3000® Ind...
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase ...
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well tolerated at all doses. SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and developme...
aTyr Pharma to Present at Upcoming Investor Conferences
aTyr Pharma to Present at Upcoming Investor Conferences SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2025. Details of the conferences appear below: Conference: RBC Capital Markets Global Healthcare ConferenceDate: Wednes...
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thor...
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence shows target market for efzofitimod in pulmonary sarcoidosis is higher than previously estimated with increased morbidity. Treatment practices in the U.S. show approximately 75% of diagnosed pulmonary sarcoidosis patients require treatment with steroi...
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635...
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 36,200 shares of aTyr’s common stock, each with an exercise price of $3.00 per share, which is equal ...
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fib...
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis Preclinical data demonstrate ATYR0101’s unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit. SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has advan...
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporat...
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be presented at ATS 2025. SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-...
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR...
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025 Findings demonstrate ATYR2810’s anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer. SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compa...
aTyr Pharma to Participate in April Investor Conferences
aTyr Pharma to Participate in April Investor Conferences SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2025. Details of the conferences appear below: Conference: Jones Healthcare and Technology Innovation Conference Date: April 8 – 9, 2025Location: Las Vegas, NVFormat: 1x1 Invest...
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635...
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors approved on March 21, 2025 an aggregate of three grants to three employees of nonstatutory stock options to purchase an aggregate of 43,800 shares of aTyr’s common stock with a wei...
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Com...
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise. Ms. Rayes brings over 25 years of experience building and leading commercial organizations at biotechnology and pharmaceuti...
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Pr...
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile. Publication in Science Translational Medicine validates efzofitimod’s mechanism of action. Company to host conference call and webcast today, March 13th at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 13, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATY...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.